People
U.S. President Joe Biden nominated Arati Prabhakar, Ph.D., to be his science advisor. If confirmed by the Senate, Prabhakar will become the first woman, first person of color and the first immigrant to hold the position.
Mark Cuban Cost Plus Drug Company now boasts over 700 prescription generic drugs for a variety of conditions, ranging from acid reflux to dementia to autoimmune diseases like Rheumatoid Arthritis.
Atreca announced that Stephen Gould, Ph.D., will be the company’s next chief scientific officer. Most recently, Gould was executive director, of Translational Oncology at Genentech.
This week’s Movers & Shakers includes a number of chief business officers and business development leaders alongside those tapped for scientific roles.
Dr. Soon-Shiong and ImmunityBio are on the final leg of what they hope will be the FDA approval of their drug N-803 (anktiva) for the treatment of bladder cancer.
Third Rock Ventures Fund VI, providing the company with $1.1 billion to invest in new life science companies. This brings Third Rock to a total of $3.8 billion across its venture funds.
The model has been validated against clinically relevant IBD therapies to demonstrate efficacy and mechanism of action, enabling drug developers to gain more accurate therapeutic insights.
Shape Therapeutics is evolving programmable RNA medicines that push the limits of current gene editing capabilities. BioSpace spoke with CSO David Huss.
Third Harmonic Bio, Akili Interactive, the Rare Disease Company Coalition, Inozyme, Athira, Cytovia and many more made major leadership decisions this week.
Greg Grunberg, who has appeared in multiple Star Wars projects, has partnered with Jazz Pharmaceuticals to bring “The Care Giver”, a video web series, to life.
PRESS RELEASES